𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The proteasomal inhibition model of Parkinson's disease: “Boon or bust”?

✍ Scribed by Flint Beal; Anthony Lang

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
54 KB
Volume
60
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neuroprotective effects of (±)-kavain in
Neuroprotective effects of (±)-kavain in the MPTP mouse model of Parkinson's disease
✍ Nicole Schmidt; Boris Ferger 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 319 KB 👁 2 views

This is the first study to investigate the potential protective effects of the lipophilic kavapyrone (+/-)-kavain in the experimental MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of Parkinson's disease (PD). Male C57BL/6 mice were treated with (+/-)-kavain (50, 100, or 200 mg/kg i.p.) o

Inhibition of the cyclooxygenase isoenzy
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease
✍ Peter Teismann; Boris Ferger 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 2 views

To study the possible role of the isoenzymes of cyclooxygenase COX-1 and COX-2 in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease we used acetylsalicylic acid, a COX-1/COX-2 inhibitor, in comparison with meloxicam, a preferential COX-2 inhibitor. As markers

Comparison between the decrease of dopam
Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models
✍ Yasushi Ito; Masahiro Fujita; Shoichi Shimada; Yoshiyuki Watanabe; Tomoya Okada; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

Early diagnosis of Parkinson's disease (PD) is important for the potential application of neuroprotective therapies. The purpose of this study was to assess the detection of the early changes of PD by either imaging the dopamine transporter (DAT) or uptake of L-3,4-dihydroxyphenylalanine (L-DOPA). A